Gary D. Steinberg, MD

Director of Bladder Cance Program NYU Langone
NYU Langone

Gary D. Steinberg, MD,
Professor Department of Urology & Perlmutter Cancer Center
Director of Goldstein Family Urology Bladder Cancer Center
NYU Langone Health
New York, New York

Gary Steinberg, MD, has been instrumental in developing innovative surgical procedures for patients with bladder cancers. Dr. Steinberg’s research includes developing new treatments for bladder cancer. He has performed over 2500 radical cystectomies and is a national leader in continent urinary tract reconstruction. He was the principal investigator for a regenerative medicine project using patient’s own stem cells to create urinary tract reconstructions without using the intestine. He is a national principal investigator, scientific advisor and protocol development advisor for multiple innovative clinical trials and translational research studies utilizing novel agents including oncolytic vaccines and immunotherapeutic agents. He is a key advisor in clinical trial design, protocol development, study completion and analysis for patients with high risk non-muscle invasive bladder cancer. He is also involved with innovative intravesical drug delivery systems and immunotherapy translational research studies. He is protocol advisor on a number of novel neoadjuvant and adjuvant therapy trials for patients with muscle invasive bladder cancer and is currently leading the development of personalized cancer vaccines for bladder cancer. He created a bladder cancer tissue bio-bank and is a key participant in The Cancer Genome Atlas (TCGA) project for muscle invasive bladder cancer. He is actively investigating genomic factors involved in therapeutic response. Dr. Steinberg is the immediate past chairperson of the Scientific Advisory Board of the Bladder Cancer Advocacy Network and serves on the executive committee of the Bladder Cancer Research Network. He has published over 250 peer review and book chapters

Disclosure information not submitted.

Presentation(s):

• Case Presentation: Do we need to Perform Radical Cystectomy for Patient who is cT0 after Neoadjuvant Chemotherapy?

  Sunday, May 15, 2022
  4:10 PM – 4:30 PM